Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.

Scott GB, Carter C, Parrish C, Wood PM, Cook G.

Cell Immunol. 2015 Sep;297(1):1-9. doi: 10.1016/j.cellimm.2015.05.002. Epub 2015 May 15.

PMID:
26051632
2.

Lenalidomide mode of action: linking bench and clinical findings.

Davies F, Baz R.

Blood Rev. 2010 Nov;24 Suppl 1:S13-9. doi: 10.1016/S0268-960X(10)70004-7. Review.

PMID:
21126632
3.

Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.

Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hajek R.

Cytometry B Clin Cytom. 2014 Jul;86(4):220-8. doi: 10.1002/cyto.b.21109. Epub 2013 Aug 6.

4.

Lenalidomide in the treatment of multiple myeloma: a review.

Armoiry X, Aulagner G, Facon T.

J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x. Review.

PMID:
18452408
5.

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.

Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, Roué G, de Larrea CF.

Haematologica. 2017 Oct;102(10):1776-1784. doi: 10.3324/haematol.2017.164632. Epub 2017 Jul 27.

6.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators.

N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.

7.

Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.

Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, Chopra R, Daniel TO, Lopez-Girona A.

Br J Haematol. 2016 Mar;172(6):889-901. doi: 10.1111/bjh.13905. Epub 2016 Feb 23.

PMID:
26914976
8.

Lenalidomide - current understanding of mechanistic properties.

Tageja N.

Anticancer Agents Med Chem. 2011 Mar;11(3):315-26. Review.

PMID:
21426296
9.

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P.

Curr Cancer Drug Targets. 2010 Mar;10(2):155-67.

PMID:
20088798
10.

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, de la Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Bladé J, Perez-Simon JA, San Miguel JF; Spanish Myeloma Group / Program Study and Treatment of Hematological Malignancies cooperative study groups.

Blood. 2016 Mar 3;127(9):1151-62. doi: 10.1182/blood-2015-10-662320. Epub 2015 Dec 14.

11.

Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.

Kim EJ, Lee JG, Kim JY, Song SH, Joo DJ, Huh KH, Kim MS, Kim BS, Kim YS.

Immunology. 2017 Dec;152(4):628-637. doi: 10.1111/imm.12804. Epub 2017 Aug 23.

PMID:
28758197
12.

Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.

De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman C, Aerts JL, Thielemans K, Schots R.

Cancer Immunol Immunother. 2014 Oct;63(10):1023-36. doi: 10.1007/s00262-014-1571-6. Epub 2014 Jun 20.

PMID:
24947180
13.

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

Busch A, Zeh D, Janzen V, Mügge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M.

Clin Exp Immunol. 2014 Aug;177(2):439-53. doi: 10.1111/cei.12343.

14.

Lenalidomide in multiple myeloma.

Kim Y, Schmidt-Wolf IG.

Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407. Epub 2015 Apr 5. Review.

PMID:
25843431
15.

Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation.

Grygorowicz MA, Borycka IS, Nowak E, Paszkiewicz-Kozik E, Rymkiewicz G, Błachnio K, Biernacka M, Bujko M, Walewski J, Markowicz S.

Clin Exp Med. 2017 May;17(2):193-207. doi: 10.1007/s10238-016-0411-8. Epub 2016 Mar 10.

PMID:
26961690
16.

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM.

Leukemia. 2009 Mar;23(3):605-7. doi: 10.1038/leu.2008.247. Epub 2008 Sep 11. No abstract available.

PMID:
18784738
17.

[The use of lenalidomide in the treatment of multiple myeloma].

Holánek M, Hájek R.

Klin Onkol. 2010;23(2):67-72. Review. Czech.

PMID:
20465083
18.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
19.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634
20.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.

Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N.

Exp Hematol. 2013 Feb;41(2):134-142.e3. doi: 10.1016/j.exphem.2012.10.004. Epub 2012 Oct 17.

PMID:
23085463

Supplemental Content

Support Center